Multidrug resistant prostate cancer cell lines DU 0.03 and PC 0.03 were established from the parental prostate cancer cell lines DU145 and PC-3 respectively by stepwise selection in doxorubicin (DOX) from 0.001 to 0.03 m mg/ml. As cells adapted to each concentration of DOX. the drug concentration was increased by 0.001 m mg/ml. The chemosensitivity of each line was determined by growth inhibition assay. The DU 0.03 and PC 0.03 lines exhibit a 5 ± 10-fold and 1.3 ± 2.8-fold increase in resistance to anthracyclines, vinblastine (VLB) and mitozantrone (Mito), respectively. Verapamil (5 m mM) partially reversed the resistance to the anthracycline and completely reversed the resistance to VLB and Mito. Drug kinetic studies measured by intracellular accumulation of 3 H-daunorubicin demonstrated a 3 fold decrease in the level of intracellular A 2 ± 4-fold increase in MRP1 mRNA levels in the drug resistant DU 0.03 and PC 0.03 lines were demonstrated by both Northern blotting and RT-PCR consistent with the ®ndings observed after staining by the two speci®c monoclonal antibodies, MRPm6 and MRPr1. Southern blot analysis demonstrated a 2-fold increase in the MRP1 gene copy number in the PC 0.03 line but not in the DU 0.03 line, suggesting that the overexpression of the MRP gene was regulated at the level of transcription in the latter line. We conclude that MRP1 not MDR1 overexpression. contributes to acquired drug resistance in these two prostate cancer cell lines. Prostate Cancer and Prostatic Diseases (2000) 3, 66±75.
Introduction
Prostate cancer is now the commonest tumour affecting the male population and its incidence is increasing. 1 The preferred therapy for advanced disease is endocrine manipulation. Although such patients often bene®t from hormonal therapy, tumours generally recur. 2 Chemotherapy has been used in this setting resulting in some palliation, 3 although prostate cancer is generally considered to be drug resistant. 4 The basis for this drug resistance is poorly understood.
Studies of potential resistance mechanisms in prostate cancer cell lines have revealed an increase in the expression of either the multidrug resistance (MDR1) gene coding for P-glycoprotein (Pgp) 5 ± 7 or multidrug resistance associated protein 1 (MRP1) encoded by the MRP1 gene, 8, 9 both of which code for trans-membrane proteins that confer cellular resistance to a variety of structurally unrelated cytotoxics such as anthracyclines and the vinca alkaloids. 10 ± 13 Although at least four other MRP1 homologues have recently been identi®ed, their role in drug resistance is unclear. 14 ± 16 Clari®cation of the mechanisms of resistance relevant to prostatic cancer is important as the strategies designed to overcome multidrug resistance may differ depending on the mechanism underlying this phenotype. As prostate cancer is increasingly being treated with mitozantrone, 3, 17, 18 a drug that is a relatively poor substrate for P-glycoprotein, 19, 20 and with the potential development of speci®c modulators of MRP1 vs Pgp-mediated drug resistance, the development of a chemotherapy-selected cell line to model the clinical situation is particularly important for the development of new therapeutic approaches. 9 We have developed a series of prostate cancer cell lines from the DU145 and PC-3 parental lines by selecting cells in increasing concentrations of doxorubicin (DOX) and have con®rmed that MRP1 is the predominant mechanism of resistance. These lines may represent a useful model for studying the mechanisms by which various genes encoding drug resistance are regulated.
Materials and methods

Materials
Doxorubicin (DOX), daunorubicin (DAU), epirubicin (EPI), vinblastine (VLB), and carboplatin (CAP) were purchased from David Bull Laboratories (Melbourne, Australia). Mitozantrone (Mito) and Verapamil (Vp) were obtained commercially from Cyanamid Pty Ltd (NSW, Australia) and Farmitalia (Melbourne, Australia), respectively. RPMI 1640 was purchased as a powder (Gibco Labs) and supplemented with 10% foetal calf serum (Trace Biosiences Pty Ltd, Melbourne, Australia), gentamicin (80 mg/ml), hepes (20 mM), sodium bicarbonate (0.21%) and glutamine (0.8 mM). Monoclonal antibodies to P-glycoprotein C219 were purchased from Novocastra Labs (Australia), and JSB-1 from BioGenex Labs (Australia). MRK 16 was generously provided by Dr Takashi Tsuruo (Division of Experimental Chemotherapy, Japanese Foundation for Cancer Research). MRP1 monoclonal antibodies MRPm6, MRPr1 were obtained from Monosan (Australia).
The cDNA probe pDHR5A was a gift from Dr M Gottesman and Dr Ira Pastan (Laboratory of Molecular Biology, National Institutes of Health, Bethesda, Maryland). The MRP1 cDNA probe was kindly provided by Dr S Cole (Queen's University, Kingston, Ontario, Canada). The cDNA glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe was a generous gift from Dr Mark Ross (Ludwig Institute for Cancer Research, Melbourne).
Establishment of drug resistant prostate cancer cell lines
To study the mechanisms of drug resistance in prostate cancer, a series of multidrug resistant cell lines were established from the parental DU145 and PC-3 cell lines by stepwise selection in gradually increasing concentrations of DOX. The PC-3 line was derived from a bone metastasis in a patient with a grade IV poorly differentiated adenocarcinoma of the prostate. 21 The prostatic carcinoma cell line DU145 was derived from a lesion in the brain of a patient with widespread metastatic carcinoma of the prostate. 22 Both lines were kindly provided by Dr W Tilley (Department of Surgery, Flinders Medical Centre, Adelaide Australia). The two lines were obtained originally from the American Type Culture Collection.
The two parental prostate cancer lines were grown in monolayers in RPMI 1640 supplemented with 10% foetal calf serum (FCS) and cultured at 37 C in a humidi®ed chamber containing 5% CO 2 in air. All lines were mycoplasma free based on the Mycoplasma T C Rapid Kit (Gen-Probe, San Diego, CA USA). Parental PC-3 and DU145 lines were selected for resistance to DOX by a stepwise increase in the concentration of DOX from 0.001 to 0.01 and 0.03 mg/ml. As cells adapted to each concentration of DOX, the drug concentration was increased by 0.001 mg/ml. It took an average of 2 weeks for the cells to be stable in each new concentration of DOX and around 13 months to be stable in the ®nal DOX concentration of 0.03 mg/ml. The resulting sublines were named according to the highest DOX concentration into which they were successfully passaged.
Growth assay
The sensitivity of each cell line to a variety of chemotherapeutic drugs was determined by a standard growth inhibition assay as described previously. 23 Brie¯y, cells were cultured in drug-free medium for at least 3 days before testing. Subcon¯uent cells in exponential growth phase were seeded in 25 cm 2¯a sks at an initial concentration of 5 6 10 4 cells/¯ask (in 10 ml of medium). Eighteen hours later, various concentrations of anthracyclines (or other anticancer drugs) were added to the culture in the presence or absence of 5 mM verapamil. The cells were incubated in humidi®ed chambers at 37 C. Three days later, cells were trypsinised in 0.05% trypsin (CSL) and 0.02% EDTA and viable cells were counted by using a phase-contrast microscope. All experiments were performed in triplicate under sterile conditions. Results were expressed as a percentage of the untreated (ie medium only) control. No signi®cant difference in growth rate was observed between drug resistant and their respective parental lines after 3 days in culture. The IC50 level for each drug was de®ned as the concentration that inhibited growth by 50% relative to untreated controls. Relative resistance represents the ratio of the IC50 of the resistant cell lines compared to the parental cell line.
RNA extraction and Northern blot analysis
RNA was isolated by the guanidinium thiocyanate phenol chloroform extraction method described by Chomczynski and Sacchi. 24 The resulting RNA pellets were transferred to microtubes, dissolved in 0.3 ml of the denaturing solution containing 4 M guanidinium thiocyanate, 25 mM sodium citrate (pH 7), 0.5% sarcosyl and 0.1 M 2-mercaptoethanol, precipitated with 2 vols of isopropanol at À20
C for 1 h, centrifuged for 10 min at 4 C and washed with 75% ethanol before being vacuum dried and dissolved in TE buffer pH 8.0 (10 mM Tris pH 7.4, 0.1 mM EDTA pH 8.0) at 2 mg/ml. Twenty micrograms of total cellular RNA were size fractionated on a 1.5% agarose gel containing 2.2 M formaldehyde and transferred onto nylon ®lters (Hybond-N, Amersham UK) for MDR1 hybridization. The ®lters were probed with the plasmid pHDR5A containing a 1.4 kb cDNA for mdr1 25 then reprobed with MRP1 cDNA and GAPDH cDNA for normalization. The pHDR5A probe predominantly recognizes the MDR1 gene under the high stringency conditions used in this study. The ®lters were prehybridized overnight at 42 C in hybridization buffer containing 50% formamide, 5 6 SSPE (1 6 SSPE containing 0.15 M NaCI, 0.00 M NaH 2 PO 4 and 0.001 M EDTA), 5 6 Denhardt's solution, 0.5% sodium dodecyl sulphate (SDS) and 1% skimmed milk powder. Hybridization was carried out in hybridization buffer. The cDNAs were randomly primed with 32 p a-dCTP (3000 Ci/mmol) and 10 6 cpm were added to each ml of hybridization buffer. The ®lters were washed sequentially in 2 6 SSPE with 0.1% SDS at 42 C for 15 min 1 6 SSPE with 0.1% SDS at 65 C for 30 min and ®nally 0.1 6 SSPE with 0.1% SDS at room temperature for 15 min. The ®lters were then exposed to X-ray ®lm at À70 C using intensifying screens or radioactive signals quantitated by scanning on a phosphorimager using Image Quant software (Molecular Dynamics, Melbourne, Australia).
RT-PCR analysis of MRP1 and MDR1 gene expression
First strand cDNA was synthesized using 1 mg of total RNA and 100 ng random hexadeoxynucleotide primers. These were heated at 95 C for 5 min and subsequently chilled on ice for 2 min. The mixture was then incubated at 37 C for 1 h in a 20 ml reaction volume containing 50 mM Tris ± HCI (pH 8.3), 3 mM MgCl 2 , 50 mM KCl, 5 mM dithiothreitol (DTT), 500 mM of each dNTP, 20 units RNAse inhibitor and 200 units of Moloney murine leukemia virus (MMLV) reverse transcriptase (Bethesda Reseach Laboratory). The reaction was heat-inactivated at 90 C for 10 min, then diluted 4-fold with water and ®nally stored at À20 C. Mock cDNA controls consisted of everything but RNA template. These were negative for MRP1, MDR1 and histone 3.3 by PCR.
An MRP1 PCR product of 252 base pairs was generated by using speci®c amplimers that reside in different exons. The sense primer was 5
H GGACCTGG-ACTTCGTTCTCA (nucleotides 4109 ± 4128) and the antisense primer was 5 H CGTCCAGACTTCCTTCATCCG (nucleotides 4381 ± 4400). 26 The MDR1 speci®c amplimers, located in different exons of the MDR1 gene, were sense 5 H CCCATCATTGCAATAGCAGG (nucleotides 2596 ± 2615) and antisense-5
H GTTCAAACTTCTG CTCC-TGA (nucleotides 2733 ± 2752) , resulting in a 157 bp product. 27 The primers for histone 3.3 were sense CCACTGAACTTCCTGATTCGC (nucleotides 282 ± 301) and antisense GCGTGCTAGCTGGATGTCTT (nucleotides 476 ± 495). These anneal to exons 2 and 3, respectively, and result in a 215 bp product. 28 To establish the exponential phase of ampli®cation, dilutions of cDNA (100, 75, 25 and 10 ng) from cell lines expressing the gene of interest were used in standard PCR reaction conditions from 21 to 35 cycles. MRP1, MDR1 and H3.3 ampli®cation was exponential between 27 and 32 cycles.
PCR was performed with cDNA derived from 50 ng of RNA (5 ml of diluted cDNA) in a ®nal volume 50 ml containing 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 2 mM MgCI 2 , 0.2 mM of each dNTP, 25 pmol of each of amplimer and 1 unit of Taq DNA polymerase (Gibco-BRL). PCR control reactions contained no cDNA. The reaction mixture was overlaid with light mineral oil and ampli®-cations were performed on an Omnigene thermocycler (Hybaid, UK). Cycling conditions included an initial denaturation at 94 C for 3 min, followed by 32 cycles at 94 C for 30 s, 57 C for 1.0 min, 72 C for 1 min, and a ®nal incubation at 72 C for 10 min. Thirty percent of each PCR product was size fractionated on a 2% agarose gel. Quantitation of PCR products was performed by¯uor-escent image analysis on the Gel DOC 1000 system using molecular Analyst software (Biorad, Australia).
Southern blot analysis of MRP1 and MDR1
High molecular weight genomic DNA was isolated from each cell line by standard techniques. 29 Brie¯y, cells harvested in exponential growth phase were lysed in lysis buffer containing 10 mM Tris/HCl, 0.1 M EDTA pH 8.0, 0.5% SDS and 20 mg/ml pancreatic RNAse at 37 C for 1 h. This was followed by incubation with proteinase K (®nal concentration 100 mg/ml) for 3 h at 50
C. The solution was then phenol/chloroform extracted and 10 M ammonium acetate and ethanol precipitated. DNA was digested with either EcoRI or Hindll. Digested DNA was electrophoretically separated on 1% agarose gel and transferred to a Hybond-N membrane. Hybridisation with random 32 P-labelled MRP1 and MDR1 cDNA was performed as described for Northern blot analysis.
Drug accumulation
The accumulation of radiolabelled daunomycin was measured as described previously. 30 Drug accumulation was performed in six-well culture plates. 1 6 10 6 cells/well of each drug resistant line and its respective parental line were plated and incubated in drug free medium overnight. The medium was replaced by 1 ml of fresh medium containing 0.25 mCi of 3 H-daunomycin (®nal concentration 0.05 mg/ml) in the presence or absence of 5 mM verapamil for varied time points. Cells were then washed three times with cold phosphate buffered saline (PBS), solublized with 0.5 M NaOH containing 0.1% Triton X100 and mixed thoroughly with 5 ml of Ultima Gold XR (Packard, Sydney) before being counted in a liquid scintillation counter.
Immunocytochemistry
An immunoperoxidase staining method was used to identify MRP1 and Pgp expression in the parental and drug resistant lines. Cells in exponential growth phase in drug free medium for at least three days were harvested and washed with cold PBS. Cytocentrifuge preparations were applied overnight at 4 C. Unbound antibodies were washed with PBS then the cells were incubated for 10 min at room temperature with streptavidin-conjugated horseradish peroxidase and incubated with a biotinylated antimouse Ig (Dako) at room temperature for 10 min. The slides were developed in a substrate solution containing diamino benzidine (DAB; 0.025% w/V) and H 2 0 2 (0.015%) in 0.05 M Tris buffer PH 7.6 for 6 min. Cells were counter-stained in haematoxylin and mounted in Hydromount.
Results
Drug resistance and the effect of verapamil
Under the phase-contrast microscope, the morphology of DOX selected drug resistant lines and their respective parental lines was identical. In addition, during a 96 h period, no signi®cant difference in growth rate between cell lines was observed (data not shown).
The chemosensitivity of each line was tested in a growth inhibition assay. The two parental prostate cancer lines showed a variable level of sensitivity to anthracyclines, but similar sensitivity to VLB (Table 1) . Compared to their respective parental lines, the DOX selected PC 0.03 and DU 0.03 lines showed a 5 ± 10-fold increase in resistance to DOX and a 4 ± 5-fold increase in resistance to two other anthracyclines (EPI and DAU). Whilst both the DOX resistant PC 0.03 and parental PC3 lines exhibited similar sensitivity to Mito, the DOX resistant DU 0.03 line showed a 1.2 ± 2.5-fold increase in resistance to Mito compared to the parental line. Both the DOX resistant PC 0.03 and DU 0.03 lines had a 2 ± 3-fold cross resistance to the ymca alkaloid VLB, but no cross resistance to CAP ( Table 1) .
The effect of Verapamil (Vp), a classical modulator of Pgp function in drug resistant cell lines was also tested. As shown (Figure 1, Table 1 ), the addition of 5 mM Vp to the culture medium had no detectable effect on the sensitivity of the parental PC-3 line, but increased the sensitivity of the parental DU145 line to EPI and DAU 2 ± 3-fold respectively. In the drug resistant lines, verapamil reversed the resistance of the DU 0.03 and PC 0.03 lines to the various drugs tested. In both resistant lines, the effect of Vp on the reversal of drug resistance was dependent on the degree of resistance. Vp (5 pM) totally reversed the low level of resistance to VLB, but only partially reversed the higher level of resistance (4 ± 9-fold increase) to DOX, EPI and DAU. There was a 2-fold reduction in the 1C50 of the DU 145 and DU 0.03 lines to Mito in the presence of Vp with a lesser but similar effect in the PC lines (Table 1) . Vp had no effect on the sensitivity of the parental and drug resistant prostate lines to CAP.
Drug kinetics
The drug kinetics of anthracyclines in the prostate cancer cell lines was measured by using radiolabelled daunorubicin ( Figure 2 ). Drug accumulation in the DOX selected PC 0.03 and DU 0.03 resistant prostate cancer lines was compared to that of their respective parental lines at the 3 h time point. Each drug resistant line accumulated approximately 3 fold less DAU than the parental line ( Figure 2 , Table 2 ).
The effect of Vp on drug accumulation was also examined in each line. The addition of 5 mM verapamil had no effect on the level of DAU accumulation in the PC-3 parental line (Figure 2 ), but signi®cantly increased DAU accumulation in the DU145 line (Table 2 ). In the presence of 5 mM Vp, the uptake of DAU was signi®cantly increased in both the resistant line, PC 0.03 and DU 0.03 lines ( Figure 2 , Table 2 ). 
Northern analysis of MRP1 and MDR1 mRNA
In order to assess MDR gene expression, total RNA from each cell line was examined at low stringency by Northern blot analysis using the MDR1 gene speci®c probe, pHDR5A. Two Pgp positive MDR cell lines, CEM/A7 and CEM/A7R, derived from a Pgp negative, T cell leukaemia cell line, CCRF-CEM by selection in DOX, used as positive and negative controls for the expression of MDR1. 30 Neither of the two parental lines PC-3 and DU145, nor the DOX selected PC 0.03 and DU 0.03 drug resistant sublines, expressed detectable MDR1 transcripts. In contrast, MRP1 mRNA was detected in both the parental and DOX selected drug resistant prostate lines (Figure 3 ). Substantially more MRP1 mRNA was observed in the parental DU145 line, compared to the PC-3 line. Phosphorimager analysis of the ratio of the MRP1 signal to the internal control (GAPDH) revealed that the level of MRP1 mRNA was 3 fold higher in the parental DU145 line than in the PC-3 line (Figure 3 ). (Fig. 3) .
Analysis of MRP1 and MDR1 gene expression by RT-PCR
The more sensitive reverse transcription/polymerase chain reaction (RT-PCR) assay was used to estimate levels of MDR1 mRNA. The cell cycle independent, ubiquitously expressed, histone 3.3 gene was used as a check of RNA integrity and as an internal standard for both MDR1 and MRP1 quantitation. PCR (32 cycles) was used to obtain MDR1 and H3.3 fragments which were size fractionated on a 2% agarose gel. A 157 bp MDR1, PCR product was seen in the positive control CEM/A7R line, whereas no detectable MDR1 expression was seen in any of the tested parental or drug resistant prostate cancer cell lines (Figure 4) .
In contrast, MRP1 gene expression was detected by RT-PCR (as expected from the Northern blots). Only a faint band was seen in the parental PC-3 or drug sensitive CCRF-CEM. A more intense band was seen in the PC 0.03, DU145 and DU 0.03 cell lines (data not shown).
Southern analysis of MRP1 gene ampli®cation
Ampli®cation of the MRP1 gene has been associated with overexpression of the MRP1 gene in a drug selected cell line. 31 Southern blot analysis of the MRP1 gene in each of the four prostate cancer lines revealed that the MRP1 probe hybridized to a single band of greater than 21.3 kb following EcoR1 digestion and to a pair of DNA bands, below 21.3 and 2.0 kb following HindII digestion ( Figure 5 ). When normalized for DNA loading (based on several separate digests), the signal intensity of PC 0.03 bands was 2-fold higher compared to PC-3, suggesting a doubling in the gene copy number in the resistant line PC 0.03 ( Figure 5 ). However, no difference in signal intensity was observed between DU145 and DU 0.03 genomic DNA (data not shown).
Immunocytochemical detection of MRP1 and Pgp expression
Two different monoclonal antibodies MRPr1 (rat immunoglobulin lgG2a) and MRPm6 (mouse IgG1) directed against different domains of MRP1 were used to localise MRP1 in the prostate cancer cell lines. 32 The HL60 and HL60/AR lines were used as negative and positive controls, respectively for MRP1 expression. MRPr1 and MRPm6 showed a membrane staining pattern in the parental and DOX selected drug resistant lines. A weak positive staining was observed in the parental DU 145 line and very faint staining in PC-3 line (Figures 6a and  d) . In the DOX selected, drug resistant lines, a strong determined from triplicate experiments as described in the Materials and methods. *P`0.01 compared with the parental line. **P`0.01 compared with the control (ie absence of verapamil). Figures 6b, c and e, f) .
Three monoclonal antibodies C219, JSB-1 and MRK16 were used to examine Pgp expression. Using recommended, standard conditions, 33 with appropriate negative and positive controls, no obvious Pgp staining was observed in the parental or drug resistant prostate cancer cell lines (data not shown).
Discussion
To clarify whether the acquisition of the multidrug resistance phenotype in prostate cancer is associated with the overexpression of the MDR1 or MRP1 gene, two multidrug resistant cell lines known as PC 0.03 and DU 0.03 were established from the parental PC-3 and DU145 lines by selection in gradually increasing concentration of DOX.
In our studies we obtained two multidrug resistant cell lines, cross-resistant to a range of structurally unrelated drugs, from each of the respective parental, prostate cancer cell lines (Figure 1 , Table 1 ). The resistance pro®le of both resistant variants could be partially reversed by Vp at a concentration of 5 mM. Drug kinetic studies involving the measurement of the accumulation of radio-labeled DAU in sensitive and resistant variants revealed a 3-fold decrease in DAU accumulation in the PC 0.03 and DU 0.03 resistant lines ( Figure 2 , Table 2 ). The addition of 5 mM Vp signi®cantly increased DAU accumulation in both resistant lines, a classical ®nding in lines that express Pgp, although not inconsistent with overexpression of the MRP1 gene.
Northern blot analysis of MDR1 mRNA revealed no evidence of MDR1 mRNA (Figure 3a ) in either the drug resistant or their parental lines. To exclude the possibility that a very low level of increased MDR1 expression (not detectable by Northern blot) may have nevertheless been suf®cient to cause a change in the levels of resistance, 34 MDR1 gene expression was further determined by using semiquantitative RT-PCR. With PCR (32 cycles), no detectable MDR1 mRNA was seen in the Pgp negative CCRF-CEM cell line or either of the two prostate cancer lines (Figure 4 ). These ®ndings were con®rmed by the failure to detect Pgp expression using immunocytochemistry. No Pgp staining was seen in the cells tested under standard recommended conditions 33 using two antibodies C219 and JSB-1 (data not shown).
In contrast, compared to the parental PC-3 and DU145 lines, a 4.4-and 2-fold increase in MRP1 mRNA expression was seen in the Northern blot analysis of the PC 0.03 and DU 0.03 lines, respectively (Figure 3) . The results were comparable to that seen in the RT-PCR assay (Figure 4 ). The two monoclonal antibodies to MRP1, MRPr1 and MRPm6 demonstrated faint staining in the PC-3 line (Figure 6a ) and weak staining in the parental DU145 line (Figure 6d ), but strongly positive staining in the drug resistant PC 0.03 and DU 0.03 lines (Figures 6b, c and d, e) .
To date, the expression of Pgp in the DU145 and PC-3 human prostate cancer cell lines has only been previously reported in a single study describing intrinsic resistance in monolayer culture. 5 In contrast, using a variety of techniques we and other investigators 9, 35 have demonstrated that Pgp expression was below detection levels in these cell lines. Although doxorubicin (DOX) selected drug resistant prostate cancer cell lines expressing Pgp have been described, they are all derived from the Dunning rat prostate cancer model. 7, 36 In drug selected, human prostate cancer cell lines, MDR1 gene overexpression has not been previously reported.
As previously demonstrated by Chin et al, 37 regulation of MDR1 gene expression between human and rodent tissue differs following treatment with cytotoxic drugs. The overexpression of MRP1 mRNA is often associated with gene ampli®cation in DOX selected MDR cell lines. 31, 39 However, MRP1 mRNA can also be elevated in the absence of an increase in the MRP1 gene copy number, indicating that MRP1 gene expression can be regulated at several levels. 40 ± 42 Southern blot analysis of EcoRI or HindIII digested genomic DNA from the PC 0.03 line and its parental line revealed a 2 fold increase in the copy number of the MRP1 gene in the PC 0.03. However, similar ®ndings were not seen in the DU 0.03 line ( Figure  5 ), suggesting that the enhanced expression of MRP1 in the absence of gene ampli®cation in the DU 0.03 drug resistant cell line, may be due to a gene mutation in the promoter region or transactivation of the MRP1 gene.
At present there are several ways to study intrinsic multidrug resistance in prostate cancer. Chen et al have observed Pgp expression in human prostate xenografts. 43 However, neither the issue of acquired resistance, nor the evaluation of MRP1 expression were addressed in this study. Wilson et al have observed that cell con¯uency had an in¯uence on the MDR phenotype. 44 Using quiescent cells, DOX resistance and Pgp expression have been reported in large DU145 multicellular tumour spheroids, whereas Pgp expression was low in exponentially growing small spheroid. 45 This could be due to the suggestion that the MDR phenotype is regulated by tissue architecture and cellular proliferation state. 46 However, Goldstein et al 47 and Sullivan et al 48 were unable to detect Pgp expression in clinical prostate cancer samples. Furthermore Nooter et al reported low levels of MRP1 expression in clinical samples. 49 Sullivan and associates 48 not only reported MRP1 overexpression in clinical prostate cancer samples, but also described an increase in the expression of this gene with advancing stage. 48 These clinical ®nd-ings are consistent with our ®ndings obtained from monolayers studies in cell lines.
Our results con®rm the recently reported clinical ®nd-ings that the mechanism underlying the development of drug resistance in patients with prostate cancer may be associated with MRP1 protein overexpression. This hypothesis is supported by a recent study of clinical specimens in which MRP1 was expressed in both normal prostatic tissue (37%) and prostatic adenocarcinoma (84%), whilst Pgp was undetectable. 48 The identi®- cation of MRP1 and not Pgp expression in these two chemotherapy-selected prostate cancer models warrants further study of MRP1 associated drug resistance and its circumvention in prostate cancer, 9 particularly given the increasing clinical use of mitozantrone to treat hormone refractory prostate cancer. 3 
